KUOW | October 31, 2023
The recent Alaska Airlines flight emergency is only one example of psychedelic mushrooms making the news this year. Nathan Sackett, MD, MS, says these incidents highlight the need to be very thoughtful and intentional about potential access to these compounds.
Crosscut | July 27, 2023
Research shows psychedelic drugs such as psilocybin and ketamine can be effective in treating depression, post-traumatic stress and substance-use disorders — but there’s still much we don’t know. Nathan Sackett, MD, MS, acting assistant professor of psychiatry and behavioral sciences in the UW School of Medicine, is interviewed.
KNDO | May 19, 2023
The University of Washington School of Medicine is conducting a study on the therapeutic value of psychedelic mushrooms led by Nathan Sackett, MD.
MyNorthwest | May 17, 2023
Governor Jay Inslee signed Senate Bill 5263 into law, which mandated a study into psilocybin as well as the creation of a regulatory body for the possible recreational and medical use of the drug. Leading the upcoming study will be Dr. Nathan Sackett, with the University of Washington’s Department of Psychiatry and Behavioral Sciences.
Right as Rain | May 17, 2023
Alcohol is so normalized in our culture that we often forget its effects on our bodies, including long-term consequences of alcohol use like cardiovascular disease, anxiety and more. Nathan Sackett is quoted.
UW Medicine Newsroom | May 16, 2023
UW Medicine, led by the Center for Novel Therapeutics in Addiction Psychiatry, will facilitate a small-scale study to explore the potential benefit of psychedelic mushrooms with psychotherapy.
Department of Psychiatry and Behavioral Sciences | March 30, 2023
The UW’s Office of Research facilitates the development of new research initiatives that cut across traditional disciplinary boundaries and sanctions the creation of new interdisciplinary Centers, Institutes, and Programs collectively referred to as ‘Organized Research Units’ (ORUs). The Center for Novel Therapeutics in Addiction Psychiatry (NTAP) is the latest initiative to become an official UW Research Center.
Policygenius | December 30, 2022
Over the last six years, psychedelic drugs have gained increasing acceptance in the medical and legal realms as legitimate treatments for mental health conditions. Nathan Sackett, MD, MS, says researchers are finding growing evidence that psychedelics can help treat conditions like depression, anxiety, and substance abuse.
Right as Rain | July 5, 2022
Ketamine can help alleviate symptoms of depression and lessen suicidal thoughts quickly, but ketamine treatment is not for everyone, says Nathan Sackett, MD, MS.
The Seattle Times | April 23, 2022
Scientists, doctors, advocacy workers, and other community members gathered to discuss the next frontier of treating substance-use disorders and addiction: psychedelics. The meeting was convened by the Center for Novel Therapeutics in Addiction Psychiatry led by Nathan Sackett, MD.